Medtronic: Don't Miss Out On This Dividend Aristocrat Deal Now (NYSE:MDT)
· seekingalpha.com
Medtronic is rated a Buy, citing Q1 2027 beat, raised FY2027 EPS guidance, solid debt metrics, and 15% undervalued. Read the latest analysis on MDT stock here.
Looking for more investing ideas like this one? Get them exclusively at The Dividend Kings. Learn more >>
While the broader market has delivered gains in recen...